RT Journal Article
T1 Prevalence of Anti-Anisakis simplex Antibodies in a Cohort of Patients with Inflammatory Bowel Disease in Norway
A1 Hoz Martín, María Piedad de la
A1 González Fernández, Juan
A1 Andreu-Ballester, Juan Carlos
A1 Hoivik, Marte L.
A1 Ricanek, Petr
A1 Bruland, Torunn
A1 Sandvik, Arne K.
A1 Cuéllar Del Hoyo, María Del Carmen
A1 Catalán-Serra, Ignacio
AB This study assessed the seroprevalence of anti-Anisakis simplex antibodies in Norwegian patients with inflammatory bowel disease (IBD), specifically ulcerative colitis (UC) and Crohn’s disease (CD), compared with healthy controls. Associations between anti-A. simplex antibody positivity and clinical or laboratory parameters in IBD were also explored. A total of 86 UC patients, 68 CD patients, and 41 healthy controls were prospectively enrolled from four Norwegian hospitals (2013–2022). Diagnosis and disease activity were established using standard clinical, endoscopic, and biomarker criteria. Serum samples were analyzed for total Ig, IgG, IgM, IgA, and IgE antibodies against A. simplex and Pseudoterranova decipiens using ELISA. Anti-A. simplex IgG seroprevalence was 4.9% in controls and 3.2% in IBD (3.5% UC, 2.9% CD). IgM seroprevalence was 0% in all groups. IgA seroprevalence was higher in IBD (16.2%) than controls (4.9%), with 14.0% in UC and 19.1% in CD. IgE seroprevalence was low across all groups. Smoking correlated with lower antibody levels and higher surgery rates. In UC, higher anti-A. simplex IgG and IgE levels were associated with milder disease and better prognosis. Anti-TNFα and azathioprine treatments were linked to higher anti-A. simplex IgA. Norwegian UC and CD patients had significantly higher anti-A. simplex total Ig and IgA seroprevalence than healthy controls, indicating increased exposure or immune response. Anti-A. simplex IgG and IgE may serve as markers of clinical activity in UC. Further research is warranted to clarify the clinical significance of these findings.
PB MDPI
SN 2076-0817
YR 2025
FD 2025-08-04
LK https://hdl.handle.net/20.500.14352/124868
UL https://hdl.handle.net/20.500.14352/124868
LA eng
NO De La Hoz-Martín MP, González-Fernández J, Andreu-Ballester JC, Hoivik ML, Ricanek P, Bruland T, Sandvik AK, Cuéllar C, Catalán-Serra I. Prevalence of Anti-Anisakis simplex Antibodies in a Cohort of Patients with Inflammatory Bowel Disease in Norway. Pathogens 2025;14:769. https://doi.org/10.3390/pathogens14080769.
DS Docta Complutense
RD 12 abr 2026